A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants
Information source: Janssen R&D Ireland
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Rilpivirine (Drug); Rifabutin (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Janssen R&D Ireland Official(s) and/or principal investigator(s): Janssen Research & Development, LLC Clinical Trial, Study Director, Affiliation: Janssen Research & Development, LLC
Summary
The purpose of this study is to explore the pharmacokinetics of different dosing regimens of
rilpivirine in combination with rifabutin in healthy participants.
Clinical Details
Official title: A Phase I, Open-Label Study in Healthy Subjects, to Explore the Pharmacokinetics of Different Dosing Regimens of Rilpivirine in Combination With Rifabutin, at Steady-State
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Pharmacokinetics of different dosing regimens of rilpivirine in combination with rifabutin, at steady-state
Secondary outcome: Number of participants with adverse events as a measure of safety and tolerability
Detailed description:
This is a Phase I, open-label (the participant will know the identity of the treatment they
receive), 3-period study to investigate the pharmacokinetic (what the body does to the
medication) interaction of steady-state (constant concentrations in your blood resulting
from a fixed dosing regimen) rilpivirine and steady-state rifabutin. Twenty healthy
participants will be enrolled and will receive 3 different treatments (treatment A:
rilpivirine 25 mg once daily administered daily for 11 days; treatment B: rilpivirine 50 mg
once daily administered for 11 days + rifabutin 300 mg daily administered for 17 days;
treatment C: rilpivirine (in a regimen to be determined based on an interim analysis of
treatments A and B) administered for 11 days + rifabutin 300 mg daily administered for 17
days). All 20 participants will be randomized (the study drug is assigned by chance) to
receive treatments A (10 participants) and treatment B (10 participants) and there will be a
washout period of at least 21 days between treatments A and B. After all participants have
completed treatments A and B, there will be an interim analysis to decide upon the dosing
regimen for rilpivirine in treatment C (the rilpivirine regimen in treatment C could be
either once daily or twice daily with a total daily dose of rilpivirine between 25 and 75
mg). All 20 participants will receive treatment C. Safety and tolerability will be evaluated
throughout the study.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Participants should be healthy on the basis of physical examination, medical history,
vital signs, electrocardiogram, and the results of blood biochemistry and hematology
tests and a urinalysis performed at screening
- Men must agree to use a highly effective method of birth control (ie, male condom
with either female intrauterine device, diaphragm, cervical cap or hormone based
contraceptives by their female partner), and to not donate sperm during the study and
for 3 months after receiving the last dose of study drug
- Women must be postmenopausal for at least 2 years, or be surgically sterile (have had
a total hysterectomy or bilateral oophorectomy, tubal ligation/bilateral tubal clips
without reversal operation, or otherwise be incapable of becoming pregnant)
- Women must have a negative pregnancy test at screening
- Participants must be non-smoking for at least 3 months prior to screening
Exclusion Criteria:
- A positive HIV-1 or HIV-2 test at screening
- History or suspicion of alcohol or barbiturate, amphetamine, recreational or narcotic
drug use which in the Investigator's opinion would compromise subject safety and/or
compliance with study procedures
- Hepatitis A, B or C infection (confirmed by hepatitis A IgM, HBsAg, or hepatitis C
virus antibody, respectively) at screening
- Currently active clinically significant gastrointestinal, cardiovascular, neurologic,
psychiatric, metabolic, endocrine, renal, hepatic, respiratory, inflammatory or
infectious disease
- Any history of tuberculosis, ocular herpes, or uveitis
- Currently significant diarrhea or gastric stasis that in the Investigator's opinion
could influence drug absorption or bioavailability
Locations and Contacts
Merksem, Belgium
Additional Information
Starting date: April 2012
Last updated: March 27, 2014
|